Literature DB >> 156825

Ageing of Neurospora crassa. VIII. Lethality and mutagenicity of ferrous ions, ascorbic acid, and malondialdehyde.

K D Munkres.   

Abstract

Ferrous ions were highly lethal and mutagenic to germinated conidia of Neurospora crassa. At comparable survival, treatment with 0.2 mM ferrous ions was 14- and 50-fold more mutagenic than ultra-violet irradiation or X-rays, respectively, in the reversion of an inositol auxotroph. Ascorbic acid alone (2 mM) was not reproducibly lethal and inhibited both the lethality and mutagenicity of ferrous ions. Bovine superoxide dismutase (SOD) completely inhibited the residual lethality of ferrous ascorbate. Protection by ascorbic acid and SOD indicates that superoxide radicals, generated by oxidation of Fe(II), are directly or indirectly mutagenic and lethal. Malondialdehyde (MDA) was lethal and appeared to be mutagenic; however, its action is probably different from that of superoxide. Therefore, superoxide-mediated production of endogenous MDA by way of peroxidation of polyunsaturated fatty acids is probably not an alternate mutagenic pathway, at least in the reversion of the allele of the inl locus examined. These results and the demonstration of superoxide-mediated decrease in the synthetic fidelity of DNA polymerase in vitro (Rana and Munkres, in preparation) warrant additional exploration of the hypothesis that endogenous cellular free radicals, generated by pre- and post-senescent metabolism, may enter into lethal and mutagenic reactions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 156825     DOI: 10.1016/0047-6374(79)90039-3

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  3 in total

1.  The chemistry of lipid peroxidation metabolites: crosslinking reactions of malondialdehyde.

Authors:  V Nair; C S Cooper; D E Vietti; G A Turner
Journal:  Lipids       Date:  1986-01       Impact factor: 1.880

2.  Mutagenesis by the autoxidation of iron with isolated DNA.

Authors:  L A Loeb; E A James; A M Waltersdorph; S J Klebanoff
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

3.  Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

Authors:  Christopher M Stephenson; Robert D Levin; Thomas Spector; Christopher G Lis
Journal:  Cancer Chemother Pharmacol       Date:  2013-05-14       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.